<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">TAK</journal-id>
<journal-id journal-id-type="hwp">sptak</journal-id>
<journal-id journal-id-type="nlm-ta">Ther Adv Cardiovasc Dis</journal-id>
<journal-title>Therapeutic Advances in Cardiovascular Disease</journal-title>
<issn pub-type="ppub">1753-9447</issn>
<issn pub-type="epub">1753-9455</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1753944712439337</article-id>
<article-id pub-id-type="publisher-id">10.1177_1753944712439337</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Pathophysiologic mechanisms of calcific aortic stenosis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Alexopoulos</surname><given-names>Alexandros</given-names></name>
</contrib>
<aff id="aff1-1753944712439337">Department of Cardiology, Athens General Hospital, Mesogeion Avenue, 154, 15669 Athens, Greece</aff>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Kaoukis</surname><given-names>Andreas</given-names></name>
</contrib>
<aff id="aff2-1753944712439337">Department of Cardiology, General Hospital of Athens ‘G. Gennimatas’, Greece, Athens, Greece</aff>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Papadaki</surname><given-names>Helen</given-names></name>
</contrib>
<aff id="aff3-1753944712439337">Department of Anatomy, School of Medicine, University of Patras, Greece, Rio, Patras, Greece</aff>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Pyrgakis</surname><given-names>Vlassios</given-names></name>
</contrib>
<aff id="aff4-1753944712439337">Department of Cardiology, General Hospital of Athens ‘G. Gennimatas’, Greece, Athens, Greece</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-1753944712439337"><email>aalexop@upatras.gr</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2012</year>
</pub-date>
<volume>6</volume>
<issue>2</issue>
<fpage>71</fpage>
<lpage>80</lpage>
<permissions>
<copyright-statement>© The Author(s), 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Calcific aortic stenosis (CAS) comprises the leading indication for valve replacement in the Western world. Until recently, progressive calcification was considered to be a passive process. Emerging evidence, however, suggests that degenerative aortic stenosis constitutes an active process involving stimulation of several pathophysiologic pathways such as inflammation and osteogenesis. In addition, CAS and atherosclerosis share common features regarding histopathology of lesions. These novel data raise a new perspective on the prevention and treatment of disease. The current article reviews the most important pathophysiologic mechanisms of senile aortic stenosis.</p>
</abstract>
<kwd-group>
<kwd>aortic</kwd>
<kwd>calcific</kwd>
<kwd>pathophysiologic</kwd>
<kwd>stenosis</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1753944712439337" sec-type="intro">
<title>Introduction</title>
<p>Aortic stenosis is the most common valvular lesion in Europe and North America [<xref ref-type="bibr" rid="bibr38-1753944712439337">Ramaraj and Sorrell, 2008</xref>]. As the incidence of acute rheumatic fever has declined, calcific aortic stenosis (CAS) has become the most common indication for surgical valve replacement in the United States [<xref ref-type="bibr" rid="bibr34-1753944712439337">Rajamannan, 2009</xref>]. Regarding population aged &gt;65 years, its incidence is 2–7% [<xref ref-type="bibr" rid="bibr38-1753944712439337">Ramaraj and Sorrell, 2008</xref>]. Interestingly, aortic sclerosis (aortic valve calcification without hemodynamic compromise) is present in more than 25% of patients older than age 65 years [<xref ref-type="bibr" rid="bibr7-1753944712439337">Boss <italic>et al</italic>. 2008</xref>].</p>
<p>Recent studies provide evidence that atherosclerosis and CAS share common features in relation to risk factors and histopathologic lesions [<xref ref-type="bibr" rid="bibr34-1753944712439337">Rajamannan, 2009</xref>]. Moreover, histopathologic evidence suggests that early lesions in CAS are not just a result secondary to aging, but an active cellular process. Recent research implies that the classical ‘response to injury hypothesis’, initially described in atherosclerosis, seems to represent the cornerstone of pathophysiology [<xref ref-type="bibr" rid="bibr50-1753944712439337">Yetkin and Waltenberger, 2009</xref>].</p>
</sec>
<sec id="section2-1753944712439337">
<title>Anatomy–histology</title>
<p>The internal collagen framework of aortic valve cusps is arranged in three layers: fibrosa, spongiosa and ventricularis. This structure provides strength, a cushion for the mechanical forces and elasticity for changes of shape during opening and closing. All three layers of the aortic valve are avascular and are innervated by adrenergic and cholinergic neural networks [<xref ref-type="bibr" rid="bibr48-1753944712439337">Xu <italic>et al</italic>. 2010</xref>].</p>
<p>Valve integrity is determined by the extracellular matrix. The quality and quantity of extracellular matrix components are dependent on the function of valvular interstitial cells (VICs) [<xref ref-type="bibr" rid="bibr40-1753944712439337">Schoen, 2005</xref>]. VICs are elongated, spindle-like cells and most of them are located in fibrosa. They display morphological and functional characteristics of fibroblasts, smooth muscle cells and myofibroblasts [<xref ref-type="bibr" rid="bibr44-1753944712439337">Taylor <italic>et al</italic>. 2003</xref>].</p>
<p>Five distinct phenotypes of VICs have been recognized:</p>
<list id="list1-1753944712439337" list-type="order">
<list-item><p>embryonic progenitor endothelial/mesenchymal VICs;</p></list-item>
<list-item><p>quiescent VICs;</p></list-item>
<list-item><p>activated VICs;</p></list-item>
<list-item><p>adult progenitor VICs;</p></list-item>
<list-item><p>osteoblastic VICs.</p></list-item></list>
<p>These cells present plasticity and are capable of changing their phenotype under certain circumstances (<xref ref-type="fig" rid="fig1-1753944712439337">Figure 1</xref>) [<xref ref-type="bibr" rid="bibr4-1753944712439337">Alexopoulos <italic>et al</italic>. 2011b</xref>; <xref ref-type="bibr" rid="bibr18-1753944712439337">Liu <italic>et al</italic>. 2007</xref>].</p>
<fig id="fig1-1753944712439337" position="float">
<label>Figure 1.</label>
<caption>
<p>Subtypes of valvular interstitial cells (VICs).</p>
</caption>
<graphic xlink:href="10.1177_1753944712439337-fig1.tif"/></fig>
<p>Not surprisingly, age-related reduction of this cellular population is accompanied by fibrous degeneration [<xref ref-type="bibr" rid="bibr44-1753944712439337">Taylor <italic>et al</italic>. 2003</xref>].</p>
</sec>
<sec id="section3-1753944712439337">
<title>Risk factors</title>
<p>Many of the risk factors for atherosclerosis are also associated with aortic valve sclerosis, which has led to the suggestion that calcific aortic valve disease is an atherosclerotic-like process. Clinical factors identified by multivariate analysis are older age, male sex, elevated serum lipoprotein (a) and low-density lipoprotein (LDL) levels, hypertension, smoking status, and shorter stature. Renal dysfunction and abnormalities in calcium and phosphate metabolism contribute also to the burden of disease. It remains unclear whether clinical risk factors associated with the presence of aortic stenosis also predict disease progression [<xref ref-type="bibr" rid="bibr10-1753944712439337">Freeman and Otto, 2010</xref>].</p>
</sec>
<sec id="section4-1753944712439337">
<title>Pathophysiology of CAS</title>
<p>Several factors lead to the activation of endothelium with subsequent expression of significant factors such as cytokines and adhesion molecules. Subendothelial accumulation of lipids and inflammatory cells comprise the early lesions which trigger a ‘response to injury’. This phase includes remodeling of extracellular matrix and transformation of quiescent VICs to activated VICs that consequently gain osteoblastic phenotype (<xref ref-type="fig" rid="fig2-1753944712439337">Figure 2</xref>) [<xref ref-type="bibr" rid="bibr4-1753944712439337">Alexopoulos <italic>et al</italic>. 2011b</xref>].</p>
<fig id="fig2-1753944712439337" position="float">
<label>Figure 2.</label>
<caption>
<p>Schematic illustration of pathophysiology of calcific aortic stenosis (ox-LDL, oxidized low-density lipoprotein; ang II, angiotensin II; qVIC, quiescent valvular interstitial cell; aVIC, activated valvular interstitial cell).</p>
</caption>
<graphic xlink:href="10.1177_1753944712439337-fig2.tif"/></fig>
<p>Expression of bone regulatory factors is related to formation of calcified nodules, lesions which represent later stages of aortic stenosis [<xref ref-type="bibr" rid="bibr35-1753944712439337">Rajamannan, 2010</xref>].</p>
<sec id="section5-1753944712439337">
<title>Mechanical forces</title>
<p>Aortic valve cusps are subjected to the unceasing influence of severe mechanical forces during the whole lifetime. It is believed that the attachment area of the aortic leaflets to the aortic root encounters the strongest mechanical influence, which may provoke endothelial dysfunction [<xref ref-type="bibr" rid="bibr34-1753944712439337">Rajamannan, 2009</xref>]. Preliminary studies suggested the ‘wear and tear’ theory in order to underline significance of mechanical stress in pathogenesis of aortic stenosis [<xref ref-type="bibr" rid="bibr50-1753944712439337">Yetkin and Waltenberger, 2009</xref>].</p>
<p>However, mechanical stress does not necessarily hold the primary role in pathogenesis. Genetically predisposed individuals in atherosclerosis and aortic valve sclerosis are very prone to mechanical forces that trigger effortlessly key molecular signaling pathways in both diseases [<xref ref-type="bibr" rid="bibr30-1753944712439337">Parolari <italic>et al</italic>. 2009</xref>].</p>
</sec>
<sec id="section6-1753944712439337">
<title>Endothelium</title>
<p>Abnormal activation of the aortic valve endothelium was observed initially in experimental hypercholesterolemia rabbits [<xref ref-type="bibr" rid="bibr34-1753944712439337">Rajamannan, 2009</xref>]. Recent research has shown increased E-selectin plasma levels in patients with severe CAS which normalize after aortic valve surgery. In addition, high levels of endothelial microparticles have been found in these patients. Endothelial microparticles are small vesicles that consist of a plasma membrane surrounding a small amount of cytosol. Inflammatory infiltration in calcified aortic valves has been related to circulating levels of endothelial microparticles. Several endothelial markers such as CD31, CD34 and von Willebrand factor were markedly expressed in tissue samples of human aortic valves derived from patients undergoing valve replacement for severe calcific, nonrheumatic aortic stenosis. Remarkably, decreased availability of nitric oxide and prostacyclin was noted in these specimens [<xref ref-type="bibr" rid="bibr30-1753944712439337">Parolari <italic>et al</italic>. 2009</xref>].</p>
</sec>
<sec id="section7-1753944712439337">
<title>Lipids</title>
<p>Initially, Otto and colleagues noted the association of lipid metabolism with CAS. Accumulation of intracellular and extracellular lipids was a constant finding in pathologic specimens [<xref ref-type="bibr" rid="bibr29-1753944712439337">Otto <italic>et al</italic>. 1994</xref>].</p>
<p>Involvement of the low-density lipoprotein receptor related proteins 5/6 (Lrp5/6) in valve calcification has been implicated in several studies [<xref ref-type="bibr" rid="bibr34-1753944712439337">Rajamannan, 2009</xref>]. The Lrp5/Wnt signaling pathway has great importance in bone remodeling. Wnt3a protein is secreted by endothelial cells and has the ability to bind to LDL receptor-related proteins Lrp5 or Lrp6 complex on the myofibroblast extracellular membrane [<xref ref-type="bibr" rid="bibr37-1753944712439337">Rajamannan <italic>et al</italic>. 2005</xref>]. This signal results in cytoplasmic accumulation of catenin which subsequently enters nucleus and interacts with proteins of the T-cell factor/lymphoid-enhancer factor-1 family affecting expression of target genes such as cyclin D, Runx2/Cbfa1, and Sox9 (<xref ref-type="fig" rid="fig3-1753944712439337">Figure 3</xref>) [<xref ref-type="bibr" rid="bibr4-1753944712439337">Alexopoulos <italic>et al</italic>. 2011b</xref>].</p>
<fig id="fig3-1753944712439337" position="float">
<label>Figure 3.</label>
<caption>
<p>Effects of the LRP5/Wnt signaling pathway on gene expression.</p>
</caption>
<graphic xlink:href="10.1177_1753944712439337-fig3.tif"/></fig>
<p>Recent research has shown that mutations in the EGFP domain of the Lrp6 receptor impairs cellular LDL clearance. In addition, double knockout mice lacking both apolipoprotein E (apoE) and Lrp5 present approximately 60% higher cholesterol levels compared with the age-matched apoE knockout mice [<xref ref-type="bibr" rid="bibr36-1753944712439337">Rajamannan, 2011</xref>]. This finding may be associated with an alternative pathway for cholesterol catabolism mediated by Lrp5. Lrp5 plays a significant role in extracellular matrix production and differentiation process of aortic VICs into osteoblasts, providing another link between lipid metabolism and aortic valve calcification [<xref ref-type="bibr" rid="bibr36-1753944712439337">Rajamannan, 2011</xref>; <xref ref-type="bibr" rid="bibr9-1753944712439337">Caira <italic>et al</italic>. 2006</xref>].</p>
</sec>
<sec id="section8-1753944712439337">
<title>Inflammation</title>
<p>Intense inflammatory infiltration has been reported in fibromyxomatous and calcified areas of degenerated aortic cusps [<xref ref-type="bibr" rid="bibr2-1753944712439337">Alexopoulos <italic>et al</italic>. 2010</xref>]. Recent evidence suggests that inflammatory cells express pro-inflammatory cytokines and neoangiogenic factors contributing to increased thermal heterogeneity in aortic valve stenosis. Temperature difference can be recorded by specially designed thermographic catheters with a sensitive thermistor at the distal tip [<xref ref-type="bibr" rid="bibr45-1753944712439337">Toutouzas <italic>et al</italic>. 2008</xref>].</p>
<p>As we mentioned above, several inflammatory mediators have been observed in diseased valves such as terminal complement complex C5b-9, interleukins (IL-1b, IL-6, IL-8), tumor necrosis factor-alpha (TNF-α) and Heat Shock Protein-60 (HSP-60) [<xref ref-type="bibr" rid="bibr30-1753944712439337">Parolari <italic>et al</italic>. 2009</xref>]. In addition, high serum levels of soluble endothelial adhesion molecules have been found in patients with severe aortic stenosis who had no history of coronary artery disease [<xref ref-type="bibr" rid="bibr50-1753944712439337">Yetkin and Waltenberger, 2009</xref>]. There is also intense expression of transforming growth factor-beta1 (TGF-β1) which binds to specific proteins of extracellular matrix and promotes cellular migration and aggregation as well as apoptosis of VICs [<xref ref-type="bibr" rid="bibr30-1753944712439337">Parolari <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr24-1753944712439337">Mohler, 2004</xref>].</p>
<p>Toll-like receptors (TLRs) on interstitial cells seem to play critical role in inflammatory response. <italic>In vitro</italic> studies have demonstrated that stimulation of TLRs activates the NF-κB pathway with subsequent expression of cytokines and bone-related factors [<xref ref-type="bibr" rid="bibr22-1753944712439337">Meng <italic>et al</italic>. 2008</xref>].</p>
<p>Recent research has shown that aortic VICs in areas containing calcific deposits showed significantly higher nuclear factor of activated T-cells (NFATc1) nuclear immunolocalization compared with noncalcified fibrocellular regions. transforming growth factor-beta1 (TGF-β1) is a member of a multigene family of transcription factors that belong to the Rel group and control T lymphocyte activation and differentiation [<xref ref-type="bibr" rid="bibr2-1753944712439337">Alexopoulos <italic>et al</italic>. 2010</xref>, <xref ref-type="bibr" rid="bibr3-1753944712439337">2011a</xref>].</p>
</sec>
<sec id="section9-1753944712439337">
<title>Extracellular matrix remodeling</title>
<p>Extracellular matrix proteins with lytic activity may exert favorable effects in a normal repair process. Nevertheless, overexpression of these factors or defective inhibitory mechanisms are responsible for valve injury [<xref ref-type="bibr" rid="bibr50-1753944712439337">Yetkin and Waltenberger, 2009</xref>].</p>
<p>Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases that are capable of degrading all kinds of extracellular matrix proteins, but also can process a number of bioactive molecules. MMP-1 colocalizes with TNF-a suggesting an association between extracellular matrix remodeling and inflammation [<xref ref-type="bibr" rid="bibr17-1753944712439337">Kaden <italic>et al</italic>. 2005</xref>]. In addition, MMP-12 contributes actively to valve mineralization by degradation of elastic fibers and subsequent calcium deposition onto fragmented elastin. Moreover, fragmented elastin not only acts as a potential nidus for mineral deposition but is also implicated in activation of osteochondrogenic pathways in VICs [<xref ref-type="bibr" rid="bibr33-1753944712439337">Perrotta <italic>et al</italic>. 2011</xref>].</p>
<p>It is well known that the activity of MMPs is dependent on their respective tissue inhibitors (TIMPs). There is much confusion about role of TIMPs in pathophysiology of aortic stenosis. As previous studies have shown conflicting results, further research is needed in order to unravel a possible connection with valve remodeling [<xref ref-type="bibr" rid="bibr17-1753944712439337">Kaden <italic>et al</italic>. 2005</xref>].</p>
<p>Apart from MMPs, several other factors with degrading activity such as cathepsins S, K and V overwhelm calcified lesions. Cathepsin S expression is more prominent in severely calcified areas while cathepsin V is related to endothelial cells [<xref ref-type="bibr" rid="bibr14-1753944712439337">Helske <italic>et al</italic>. 2006b</xref>]. Interestingly, intense elastolysis and inflammation are associated with high levels of cathepsin S whereas valve mineralization is diminished in cathepsin S-deficient mice [<xref ref-type="bibr" rid="bibr1-1753944712439337">Aikawa <italic>et al</italic>. 2009</xref>]. Moreover, colocalization of cathepsin G and TGF-β1 in mast cells lends further support to hypothesis that inflammation is the underlying cause of calcification [<xref ref-type="bibr" rid="bibr13-1753944712439337">Helske <italic>et al</italic>. 2006a</xref>].</p>
<p>Another extracellular matrix glycoprotein, tenascin-C, presents abundant expression in calcified valves. Tenascin-C is a highly conserved, multifunctional protein implicated in cell proliferation, migration, differentiation and apoptosis [<xref ref-type="bibr" rid="bibr46-1753944712439337">Wallner <italic>et al</italic>. 1999</xref>]. Emerging evidence suggests that tenascin-C enhances alkaline phosphatase (ALP) activity and expression of MMPs promoting calcium deposition in degenerative lesions [<xref ref-type="bibr" rid="bibr50-1753944712439337">Yetkin and Waltenberger, 2009</xref>; <xref ref-type="bibr" rid="bibr24-1753944712439337">Mohler, 2004</xref>].</p>
<p>Upregulation of cystatin C, a cysteine protease inhibitor, has been found in calcific human aortic valves. Its presence must not be considered circumstantial as a previous study reported increased expression in mature osteoblasts [<xref ref-type="bibr" rid="bibr15-1753944712439337">Huh <italic>et al</italic>. 1995</xref>].</p>
</sec>
<sec id="section10-1753944712439337">
<title>Valvular interstitial cells</title>
<p>Osteoblastic phenotype of VICs implies expression of bone proteins exhibiting regulatory or structural role. VICs in calcified lesions show significantly higher expression of bone regulatory factors such as bone morphogenetic protein (BMP), Runx2/Cbfa1 and Osterix in relation to noncalcified areas [<xref ref-type="bibr" rid="bibr2-1753944712439337">Alexopoulos <italic>et al</italic>. 2010</xref>; <xref ref-type="bibr" rid="bibr34-1753944712439337">Rajamannan, 2009</xref>]. Sox9, a critical regulator of both early and late stages of chondrogenesis is overexpressed in stenotic aortic valves [<xref ref-type="bibr" rid="bibr2-1753944712439337">Alexopoulos <italic>et al</italic>. 2010</xref>]. Several lines of evidence suggest an important role of the OPG/RANKL/RANK (osteoprotegerin/receptor activator of NF-κB ligand/receptor activator of NF-κB) axis in valve pathology [<xref ref-type="bibr" rid="bibr19-1753944712439337">Mallat and Tedgui, 2004</xref>]. Specifically, in cultured human aortic valve myofibroblasts, RANKL enhances the expression of osteoblast-related genes promoting calcium deposition in extracellular matrix [<xref ref-type="bibr" rid="bibr16-1753944712439337">Kaden <italic>et al</italic>. 2004</xref>]. This phenotype of interstitial cells was also found to be related with high levels of TLRs 2 and 4. Activation of these receptors may lead to increased expression of cytokines and osteogenic factors such as BMP-2 and Runx2/Cbfa1 [<xref ref-type="bibr" rid="bibr49-1753944712439337">Yang <italic>et al</italic>. 2009</xref>].</p>
</sec>
<sec id="section11-1753944712439337">
<title>Genetic influence</title>
<p>Activation of signaling pathways is dependent on the expression of inhibitory proteins. Recent evidence has shown that BMP is inhibited by several proteins such as noggin, chordin, follistatin, gremlin and Smad proteins. Relative deficiency of these factors could be responsible for aortic valve ossification [<xref ref-type="bibr" rid="bibr24-1753944712439337">Mohler, 2004</xref>].</p>
<p>Determination of allelic variants of lipoproteins in patients suffering from aortic stenosis comprises an interesting research topic. Although a higher prevalence of apoE2 and apoE4 has been observed in some studies, these results have not been affirmed by other researchers [<xref ref-type="bibr" rid="bibr26-1753944712439337">Novaro <italic>et al</italic>. 2003</xref>].</p>
<p>Inflammation is a prerequisite for aortic valve calcification. Polymorphisms of the IL-10 gene promoter as well as simultaneous presence of the rare chemochine receptor 5 and connective tissue growth factor alleles are associated with severe calcium burden in patients with aortic stenosis [<xref ref-type="bibr" rid="bibr30-1753944712439337">Parolari <italic>et al</italic>. 2009</xref>].</p>
<p>Regarding bone metabolism genomics, vitamin D receptor genetic polymorphism has been extensively investigated [<xref ref-type="bibr" rid="bibr27-1753944712439337">Ortlepp <italic>et al</italic>. 2001</xref>]. High incidence of the B allele has been found in aortic stenosis and is related with reduced calcium absorption, bone resorption and increased expression of parathormone [<xref ref-type="bibr" rid="bibr30-1753944712439337">Parolari <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr34-1753944712439337">Rajamannan, 2009</xref>]. Targeted loss of Sox9 function during valve development is related to predisposition for calcific valve phenotype in adulthood [<xref ref-type="bibr" rid="bibr32-1753944712439337">Peacock <italic>et al</italic>. 2010</xref>]. Runx2/Cbfa1, a master transcription factor for bone formation, induces transcription of osteoblast-related genes such as osteocalcin gene [<xref ref-type="bibr" rid="bibr2-1753944712439337">Alexopoulos <italic>et al</italic>. 2010</xref>, <xref ref-type="bibr" rid="bibr3-1753944712439337">2011a</xref>]. Transcriptional activity of Runx2/Cbfa1 and Sox9 may be affected by Notch1 signaling. Recent research demonstrated that mutations of the Notch1 gene are associated with enhanced calcium deposition in aortic valves probably via enhanced Runx2/Cbfa1 and attenuated Sox9 expression [<xref ref-type="bibr" rid="bibr21-1753944712439337">Meier-Steigen <italic>et al</italic>. 2010</xref>; <xref ref-type="bibr" rid="bibr20-1753944712439337">Mead and Yutzev, 2009</xref>; <xref ref-type="bibr" rid="bibr11-1753944712439337">Garg <italic>et al</italic>. 2005</xref>].</p>
<p>Finally, a polymorphism of the alpha estrogen receptor in postmenopausal women is related to increase of cholesterol levels and predisposition to aortic valve calcification [<xref ref-type="bibr" rid="bibr25-1753944712439337">Nordstrom <italic>et al</italic>. 2003</xref>].</p>
</sec>
<sec id="section12-1753944712439337">
<title>Other factors</title>
<p>High levels of angiotensin-converting enzyme have been observed in fibromyxomatous lesions presenting increased LDL and apoB concentration. It is speculated that plasma lipoproteins promote retention of angiotensin-converting enzyme [<xref ref-type="bibr" rid="bibr30-1753944712439337">Parolari <italic>et al</italic>. 2009</xref>]. Lisinopril managed to attenuate the presence of angiotensin-converting enzyme in experimental models [<xref ref-type="bibr" rid="bibr43-1753944712439337">Sun <italic>et al</italic>. 1995</xref>]. Members of the renin–angiotensin system are implicated in mechanisms of repair of the aortic valve as a normal response to injury. However, hyperactivation of the renin–angiotensin system exerts deleterious effects leading to pathologic fibrosis [<xref ref-type="bibr" rid="bibr24-1753944712439337">Mohler, 2004</xref>].</p>
<p>Several studies have confirmed neovessel formation in calcified valves [<xref ref-type="bibr" rid="bibr41-1753944712439337">Soini <italic>et al</italic>. 2003</xref>]. Angiogenesis may be implicated in calcification process by various ways including recruitment of inflammatory cells, transdifferentiation of pericytes of the neovessel wall and secretion of cytokines from activated endothelial cells [<xref ref-type="bibr" rid="bibr2-1753944712439337">Alexopoulos <italic>et al</italic>. 2010</xref>]. The whole process is related with increased levels of endothelial nitric oxide synthase, vascular endothelial growth factor (VEGF) and its receptors Flt-1 and Flk-1 [<xref ref-type="bibr" rid="bibr30-1753944712439337">Parolari <italic>et al</italic>. 2009</xref>]. Recent research has demonstrated high levels of periostin in areas of neoangiosis in degenerated valves. Periostin is expressed by VICs and inflammatory cells and not only exerts angiogenic activity but also enhances secretion of MMPs [<xref ref-type="bibr" rid="bibr12-1753944712439337">Hakuno <italic>et al</italic>. 2010</xref>]. Angiogenesis comprises an attractive diagnostic and therapeutic target. ανβ3-integrin targeted nanoparticles bearing gadolinium chelates can be used to image neovessels in atherosclerotic lesions with proton MRI [<xref ref-type="bibr" rid="bibr47-1753944712439337">Waters <italic>et al</italic>. 2008</xref>]. Notably, low-grade lesions are characterized by greater neoangiosis relatively to severe lesions suggesting a temporal pattern of the phenomenon in development of aortic stenosis [<xref ref-type="bibr" rid="bibr41-1753944712439337">Soini <italic>et al</italic>. 2003</xref>]. Considering the fact that neoangiosis is characterized by a short time window as it takes place in days or months, potent therapeutic intervention must be timely and targeted [<xref ref-type="bibr" rid="bibr30-1753944712439337">Parolari <italic>et al</italic>. 2009</xref>].</p>
<p>Great effort has been made by several researchers in order to relate infectious agents with aortic stenosis but data are conflicting. Recently, the presence of nanobacteria, growing self-replicating calcifying nanoparticles that potentially represent new pathogens, was indicated in aortic valve specimens collected at surgery. Their expression has been noted already in carotid disease and abdominal aorta aneurysms [<xref ref-type="bibr" rid="bibr8-1753944712439337">Bratos-Perez <italic>et al</italic>. 2008</xref>].</p>
</sec></sec>
<sec id="section13-1753944712439337">
<title>Treatment effects on pathophysiologic mechanisms</title>
<sec id="section14-1753944712439337">
<title>Statins</title>
<p>The role of statins is not limited to cholesterol-lowering effects. The JUPITER (Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin) trial showed that statin therapy in patients with normal cholesterol levels but elevated C-reactive protein is related with reduced cardiovascular morbidity and mortality. These findings suggest that statins possess beneficial anti-inflammatory and anticoagulant properties [<xref ref-type="bibr" rid="bibr31-1753944712439337">Parolari <italic>et al</italic>. 2011</xref>]. In contrast to mild forms of disease, findings are inconsistent in patients with moderate to severe degrees of aortic stenosis [<xref ref-type="bibr" rid="bibr30-1753944712439337">Parolari <italic>et al</italic>. 2009</xref>].</p>
<p>Previous reports suggest that expression of MMPs is reduced by VICs and macrophages under the effect of statin treatment [<xref ref-type="bibr" rid="bibr24-1753944712439337">Mohler, 2004</xref>]. TGF-β is an important regulator of cellular proliferation and differentiation and modulator of inflammation and extracellular matrix remodeling. Several studies provide evidence that levels of TGF-β in human VICs are reduced with implementation of statin treatment in initial stages of disease. This results in attenuated presence of ALP and osteocalcin in calcified lesions [<xref ref-type="bibr" rid="bibr28-1753944712439337">Osman <italic>et al</italic>. 2006</xref>]. However, these findings were not confirmed in late stages of disease indicating the narrow therapeutic time window of statins [<xref ref-type="bibr" rid="bibr5-1753944712439337">Anger <italic>et al</italic>. 2009</xref>].</p>
<p>Statins are shown to attenuate leukocyte infiltration and expression of bone regulatory factors in aortic valves of experimental models with hypercholesterolemia [<xref ref-type="bibr" rid="bibr34-1753944712439337">Rajamannan, 2009</xref>]. These effects are attributed to modulation of Lrp5 pathway and endothelial nitric oxide synthase [<xref ref-type="bibr" rid="bibr16-1753944712439337">Kaden <italic>et al</italic>. 2004</xref>]. They also reduce the expression of regulators of G protein-mediated signaling proteins (RGS) in calcified valves triggering activation of extracellular-regulated kinases that enhance proliferation of myofibroblasts [<xref ref-type="bibr" rid="bibr30-1753944712439337">Parolari <italic>et al</italic>. 2009</xref>].</p>
<p>On the other hand, increased expression of BMP-2 has been observed in experimental models treated with HMG-CoA reductase inhibitors [<xref ref-type="bibr" rid="bibr5-1753944712439337">Anger <italic>et al</italic>. 2009</xref>]. Atorvastatin also extenuates the activity of ALP in cultured interstitial aortic cells in contrast to bone tissue where it exerts an opposite effect [<xref ref-type="bibr" rid="bibr23-1753944712439337">Miller <italic>et al</italic>. 2008</xref>]. These contradictory findings, called the ‘statin paradox’, suggest that the beneficial impact could be time-dependent and beyond this time window statins exhibit neutral or even harmful effects. A possible explanation is that different cell populations prevail during several stages of pathophysiologic process resulting in variable response to statin treatment. This could be related to the results of several trials that failed to demonstrate positive therapeutic effects [<xref ref-type="bibr" rid="bibr30-1753944712439337">Parolari <italic>et al</italic>. 2009</xref>]. In the SALTIRE (Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression), SEAS (Simvastatin and Ezetimibe in Aortic Stenosis study) and ASTRONOMER (Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin) studies, statin therapy had no effect on the rate of progression of aortic stenosis. Further projects such as STOP AS (Therapy on the Progression of Calcific Valvular Aortic Stenosis), AORTICA (Efficacy of Fluvastatin on Inflammatory Markers in the Hemodynamic Progression of Degenerative Aortic Stenosis) and STAAT (Statin Therapy in Asymptomatic Aortic Stenosis) are under way to try to define the role of statins in pathophysiologic process [<xref ref-type="bibr" rid="bibr39-1753944712439337">Salas <italic>et al</italic>. 2011</xref>]. Meanwhile, there is no indication for statin use specific to aortic stenosis [<xref ref-type="bibr" rid="bibr50-1753944712439337">Yetkin and Waltenberger, 2009</xref>].</p>
</sec>
<sec id="section15-1753944712439337">
<title>Other treatment modalities</title>
<p>As we discussed earlier, angiotensin-converting enzyme exhibits intense presence in diseased valves. Preliminary reports suggest that olmesartan, an angiotensin type 1 receptor antagonist, preserves endothelial integrity and inhibits transdifferentiation of VICs into myofibroblasts or osteoblasts [<xref ref-type="bibr" rid="bibr6-1753944712439337">Arishiro <italic>et al</italic>. 2007</xref>]. Nevertheless, there is no current recommendation for use of angiotensin-converting enzyme inhibitors in order to delay progression of calcific aortic stenosis. The current trial ROCK-AS (The Potential of Candesartan to Retard the Progression of Aortic Stenosis) may provide more evidence regarding involvement of angiotensin-converting enzyme in inflammation, calcification, lipid accumulation and fibrosis [<xref ref-type="bibr" rid="bibr39-1753944712439337">Salas <italic>et al</italic>. 2011</xref>].</p>
<p>Bisphosphonates inhibit bone resorption and are widely used for the prevention and treatment of osteoporosis. Previous studies have shown that cardiovascular calcification is associated with decreased bone density suggesting complex pathophysiologic mechanisms. Interestingly, progression of aortic valve disease is slower in patients receiving bisphosphonates for osteoporosis but further research is needed in order to confirm these findings [<xref ref-type="bibr" rid="bibr39-1753944712439337">Salas <italic>et al</italic>. 2011</xref>].</p>
<p>Aortic valve replacement comprises mainstay of treatment in severe disease but many patients are not eligible as they suffer from several comorbidities. Transcatheter aortic valve implantation (TAVI) is an alternative method that offers substantial improvements in symptoms. Balloon aortic valvuloplasty (BAV), the least invasive percutaneous option, is associated with early restenosis. However, novel improvements of technique, such as use of drug eluting balloons, promise long-lasting results [<xref ref-type="bibr" rid="bibr42-1753944712439337">Spargias <italic>et al</italic>. 2009</xref>].</p>
</sec></sec>
<sec id="section16-1753944712439337" sec-type="conclusions">
<title>Conclusions</title>
<p>Age-related aortic valve calcification comprises a complex process involving activation of major molecular pathways. Several risk factors trigger a response to injury with subsequent inflammatory infiltration. Enhanced expression of inflammatory mediators is associated with activation of VICs that mediate valve mineralization. Remodeling of extracellular matrix and neoangiosis are prominent features in aortic valve lesions. Currently, the only effective treatment for severe symptomatic aortic stenosis is valve replacement and further elucidation of underlying mechanisms is needed in order to achieve integrated prevention and treatment of disease.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure"><p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p></fn>
<fn fn-type="conflict"><p>The authors declare no conflicts of interest in preparing this article.</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aikawa</surname><given-names>E.</given-names></name>
<name><surname>Aikawa</surname><given-names>M.</given-names></name>
<name><surname>Libby</surname><given-names>P.</given-names></name>
<name><surname>Figueiredo</surname><given-names>J.</given-names></name>
<name><surname>Rusanescu</surname><given-names>G.</given-names></name>
<name><surname>Iwamoto</surname><given-names>Y.</given-names></name>
<etal/>
</person-group>. (<year>2009</year>) <article-title>Arterial and aortic valve calcification abolished by elastolytic cathepsin S deficiency in chronic renal disease</article-title>. <source>Circulation</source> <volume>119</volume>: <fpage>1785</fpage>–<lpage>1794</lpage>.</citation>
</ref>
<ref id="bibr2-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alexopoulos</surname><given-names>A.</given-names></name>
<name><surname>Bravou</surname><given-names>V.</given-names></name>
<name><surname>Peroukides</surname><given-names>S.</given-names></name>
<name><surname>Kaklamanis</surname><given-names>L.</given-names></name>
<name><surname>Varakis</surname><given-names>J.</given-names></name>
<name><surname>Alexopoulos</surname><given-names>D.</given-names></name>
<etal/>
</person-group>. (<year>2010</year>) <article-title>Bone regulatory factors NFATc1 and Osterix in human calcific aortic valves</article-title>. <source>Int J Cardiol</source> <volume>139</volume>: <fpage>142</fpage>–<lpage>149</lpage>.</citation>
</ref>
<ref id="bibr3-1753944712439337">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Alexopoulos</surname><given-names>A.</given-names></name>
<name><surname>Michelakakis</surname><given-names>N.</given-names></name>
<name><surname>Papadaki</surname><given-names>H.</given-names></name>
</person-group> (<year>2011a</year>) <article-title>Pathophysiologic mechanisms of age-related aortic valve calcification</article-title>. In <person-group person-group-type="editor">
<name><surname>Masanori</surname><given-names>H.</given-names></name>
</person-group> (ed.), <source>Aortic Stenosis: etiology, Pathophysiology and Treatment</source>. <publisher-name>Intechweb</publisher-name>.</citation>
</ref>
<ref id="bibr4-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alexopoulos</surname><given-names>A.</given-names></name>
<name><surname>Peroukides</surname><given-names>S.</given-names></name>
<name><surname>Bravou</surname><given-names>V.</given-names></name>
<name><surname>Varakis</surname><given-names>J.</given-names></name>
<name><surname>Pyrgakis</surname><given-names>V.</given-names></name>
<name><surname>Papadaki</surname><given-names>H.</given-names></name>
</person-group> (<year>2011b</year>) <article-title>Implication of bone regulatory factors in human coronary artery calcification</article-title>. <source>Artery Res</source> <volume>5</volume>: <fpage>101</fpage>–<lpage>108</lpage>.</citation>
</ref>
<ref id="bibr5-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Anger</surname><given-names>T.</given-names></name>
<name><surname>Carson</surname><given-names>W.</given-names></name>
<name><surname>Weyand</surname><given-names>M.</given-names></name>
<name><surname>Daniel</surname><given-names>W.G.</given-names></name>
<name><surname>Hoeher</surname><given-names>M.</given-names></name>
<name><surname>Garlichs</surname><given-names>C.D.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Atherosclerotic inflammation triggers osteogenic bone transformation in calcified and stenotic human aortic valves: still a matter of debate</article-title>. <source>Exp Mol Pathol</source> <volume>86</volume>: <fpage>10</fpage>–<lpage>17</lpage>.</citation>
</ref>
<ref id="bibr6-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arishiro</surname><given-names>K.</given-names></name>
<name><surname>Hoshiga</surname><given-names>M.</given-names></name>
<name><surname>Negoro</surname><given-names>N.</given-names></name>
<name><surname>Jin</surname><given-names>D.</given-names></name>
<name><surname>Takai</surname><given-names>S.</given-names></name>
<name><surname>Miyazaki</surname><given-names>M.</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits</article-title>. <source>J Am Coll Cardiol</source> <volume>49</volume>: <fpage>1482</fpage>–<lpage>1489</lpage>.</citation>
</ref>
<ref id="bibr7-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Boss</surname><given-names>Y.</given-names></name>
<name><surname>Mathieu</surname><given-names>P.</given-names></name>
<name><surname>Pibarot</surname><given-names>P.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Genomics: the next step to elucidate the etiology of calcific aortic valve stenosis</article-title>. <source>J Am Coll Cardiol</source> <volume>51</volume>: <fpage>1327</fpage>–<lpage>1336</lpage>.</citation>
</ref>
<ref id="bibr8-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bratos-Perez</surname><given-names>M.A.</given-names></name>
<name><surname>Sanchez</surname><given-names>P.L.</given-names></name>
<name><surname>Garcia de Cruz</surname><given-names>S.</given-names></name>
<name><surname>Villacorta</surname><given-names>E.</given-names></name>
<name><surname>Palacios</surname><given-names>I.F.</given-names></name>
<name><surname>Fernandez-Fernandez</surname><given-names>J.M.</given-names></name>
<etal/>
</person-group>. (<year>2008</year>) <article-title>Association between self-replicating calcifying nanoparticles and aortic stenosis: a possible link to valve calcification</article-title>. <source>Eur Heart J</source> <volume>29</volume>: <fpage>371</fpage>–<lpage>376</lpage>.</citation>
</ref>
<ref id="bibr9-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Caira</surname><given-names>F.C.</given-names></name>
<name><surname>Stock</surname><given-names>S.R.</given-names></name>
<name><surname>Gleason</surname><given-names>T.G.</given-names></name>
<name><surname>McGee</surname><given-names>E.C.</given-names></name>
<name><surname>Huang</surname><given-names>J.</given-names></name>
<name><surname>Bonow</surname><given-names>R.O.</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation</article-title>. <source>J Am Coll Cardiol</source> <volume>2006.2002.2040v2001</volume>: <fpage>1707</fpage>–<lpage>1712</lpage>.</citation>
</ref>
<ref id="bibr10-1753944712439337">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Freeman</surname><given-names>R.</given-names></name>
<name><surname>Otto</surname><given-names>C.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Aortic valve disease</article-title>. In <person-group person-group-type="editor">
<name><surname>Fuster</surname><given-names>V.</given-names></name>
<name><surname>Walsh</surname><given-names>R.</given-names></name>
<name><surname>Harrington</surname><given-names>R.</given-names></name>
</person-group> (eds), <source>Hurst’s the Heart</source> (<edition>13th ed.</edition>). <publisher-loc>New York</publisher-loc>: <publisher-name>McGraw-Hill</publisher-name>.</citation>
</ref>
<ref id="bibr11-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Garg</surname><given-names>V.</given-names></name>
<name><surname>Muth</surname><given-names>A.N.</given-names></name>
<name><surname>Ransom</surname><given-names>J.F.</given-names></name>
<name><surname>Schluterman</surname><given-names>M.K.</given-names></name>
<name><surname>Barnes</surname><given-names>R.</given-names></name>
<name><surname>King</surname><given-names>I.N.</given-names></name>
<etal/>
</person-group>. (<year>2005</year>) <article-title>Mutations in NOTCH1 cause aortic valve disease</article-title>. <source>Nature</source> <volume>437</volume>: <fpage>270</fpage>–<lpage>274</lpage>.</citation>
</ref>
<ref id="bibr12-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hakuno</surname><given-names>D.</given-names></name>
<name><surname>Kimura</surname><given-names>N.</given-names></name>
<name><surname>Yoshioka</surname><given-names>M.</given-names></name>
<name><surname>Mukai</surname><given-names>M.</given-names></name>
<name><surname>Kimura</surname><given-names>T.</given-names></name>
<name><surname>Okada</surname><given-names>Y.</given-names></name>
<etal/>
</person-group>. (<year>2010</year>) <article-title>Periostin advances atherosclerotic and rheumatic cardiac valve degeneration by inducing angiogenesis and MMP production in humans and rodents</article-title>. <source>J Clin Invest</source> <volume>120</volume>: <fpage>2292</fpage>–<lpage>2306</lpage>.</citation>
</ref>
<ref id="bibr13-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Helske</surname><given-names>S.</given-names></name>
<name><surname>Syvaranta</surname><given-names>S.</given-names></name>
<name><surname>Kupari</surname><given-names>M.</given-names></name>
<name><surname>Lappalainen</surname><given-names>J.</given-names></name>
<name><surname>Laine</surname><given-names>M.</given-names></name>
<name><surname>Lommi</surname><given-names>J.</given-names></name>
<etal/>
</person-group>. (<year>2006a</year>) <article-title>Possible role for mast cell-derived cathepsin G in the adverse remodelling of stenotic aortic valves</article-title>. <source>Eur Heart J</source> <volume>27</volume>: <fpage>1495</fpage>–<lpage>1504</lpage>.</citation>
</ref>
<ref id="bibr14-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Helske</surname><given-names>S.</given-names></name>
<name><surname>Syvaranta</surname><given-names>S.</given-names></name>
<name><surname>Lindstedt</surname><given-names>K.A.</given-names></name>
<name><surname>Lappalainen</surname><given-names>J.</given-names></name>
<name><surname>Oorni</surname><given-names>K.</given-names></name>
<name><surname>Mayranpaa</surname><given-names>M.I.</given-names></name>
<etal/>
</person-group>. (<year>2006b</year>) <article-title>Increased expression of elastolytic cathepsins S, K, and V and their inhibitor cystatin C in stenotic aortic valves</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <volume>26</volume>: <fpage>1791</fpage>–<lpage>1798</lpage>.</citation>
</ref>
<ref id="bibr15-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Huh</surname><given-names>C.</given-names></name>
<name><surname>Nagle</surname><given-names>J.W.</given-names></name>
<name><surname>Kozak</surname><given-names>C.A.</given-names></name>
<name><surname>Abrahamson</surname><given-names>M.</given-names></name>
<name><surname>Karlsson</surname><given-names>S.</given-names></name>
</person-group> (<year>1995</year>) <article-title>Structural organization, expression and chromosomal mapping of the mouse cystatin-C-encoding gene (Cst3)</article-title>. <source>Gene</source> <volume>152</volume>: <fpage>221</fpage>–<lpage>226</lpage>.</citation>
</ref>
<ref id="bibr16-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kaden</surname><given-names>J.J.</given-names></name>
<name><surname>Bickelhaupt</surname><given-names>S.</given-names></name>
<name><surname>Grobholz</surname><given-names>R.</given-names></name>
<name><surname>Haase</surname><given-names>K.K.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Receptor activator of nuclear factor [kappa] B ligand and osteoprotegerin regulate aortic valve calcification</article-title>. <source>J Mol Cell Cardiol</source> <volume>36</volume>: <fpage>57</fpage>–<lpage>66</lpage>.</citation>
</ref>
<ref id="bibr17-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kaden</surname><given-names>J.J.</given-names></name>
<name><surname>Dempfle</surname><given-names>C.E.</given-names></name>
<name><surname>Grobholz</surname><given-names>R.</given-names></name>
<name><surname>Fischer</surname><given-names>C.S.</given-names></name>
<name><surname>Vocke</surname><given-names>D.C.</given-names></name>
<name><surname>Kill</surname><given-names>R.</given-names></name>
<etal/>
</person-group>. (<year>2005</year>) <article-title>Inflammatory regulation of extracellular matrix remodeling in calcific aortic valve stenosis</article-title>. <source>Cardiovasc Pathol</source> <volume>14</volume>: <fpage>80</fpage>–<lpage>87</lpage>.</citation>
</ref>
<ref id="bibr18-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Liu</surname><given-names>A.C</given-names></name>
<name><surname>Joag</surname><given-names>V.R.</given-names></name>
<name><surname>Gotlieb</surname><given-names>A.I.</given-names></name>
</person-group> (<year>2007</year>) <article-title>The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology</article-title>. <source>Am J Pathol</source> <volume>171</volume>: <fpage>1407</fpage>–<lpage>1418</lpage>.</citation>
</ref>
<ref id="bibr19-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mallat</surname><given-names>Z.</given-names></name>
<name><surname>Tedgui</surname><given-names>A.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Unbalanced RANKL/RANK pathway in aortic valve sclerosis</article-title>. <source>J Mol Cell Cardiol</source> <volume>36</volume>: <fpage>17</fpage>–<lpage>19</lpage>.</citation>
</ref>
<ref id="bibr20-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mead</surname><given-names>T.</given-names></name>
<name><surname>Yutzev</surname><given-names>K.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Notch pathway regulation of chondrocyte differentiation and proliferation during appendicular and axial skeleton development</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>106</volume>: <fpage>14420</fpage>–<lpage>14425</lpage>.</citation>
</ref>
<ref id="bibr21-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meier-Stiegen</surname><given-names>F.</given-names></name>
<name><surname>Schwanbeck</surname><given-names>R.</given-names></name>
<name><surname>Bernoth</surname><given-names>K.</given-names></name>
<name><surname>Martini</surname><given-names>S.</given-names></name>
<name><surname>Hieronymus</surname><given-names>T.</given-names></name>
<name><surname>Ruau</surname><given-names>D.</given-names></name>
<etal/>
</person-group>. (<year>2010</year>) <article-title>Activated Notch1 target genes during embryonic cell differentiation depend on the cellular context and include lineage determinants and inhibitors</article-title>. <source>PLoS One</source> <volume>5</volume>: <fpage>e11481</fpage>.</citation>
</ref>
<ref id="bibr22-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meng</surname><given-names>X.</given-names></name>
<name><surname>Ao</surname><given-names>L.</given-names></name>
<name><surname>Song</surname><given-names>Y.</given-names></name>
<name><surname>Babu</surname><given-names>A.</given-names></name>
<name><surname>Yang</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>M.</given-names></name>
<etal/>
</person-group>. (<year>2008</year>) <article-title>Expression of functional Toll-like receptors 2 and 4 in human aortic valve interstitial cells: potential roles in aortic valve inflammation and stenosis</article-title>. <source>Am J Physiol Cell Physiol</source> <volume>294</volume>: <fpage>C29</fpage>–<lpage>C35</lpage>.</citation>
</ref>
<ref id="bibr23-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miller</surname><given-names>J.D.</given-names></name>
<name><surname>Chu</surname><given-names>Y.</given-names></name>
<name><surname>Brooks</surname><given-names>R.M.</given-names></name>
<name><surname>Richenbacher</surname><given-names>W.E.</given-names></name>
<name><surname>Pena-Silva</surname><given-names>R.</given-names></name>
<name><surname>Heistad</surname><given-names>D.D.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Dysregulation of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvular stenosis in humans</article-title>. <source>J Am Coll Cardiol</source> <volume>52</volume>: <fpage>843</fpage>–<lpage>850</lpage>.</citation>
</ref>
<ref id="bibr24-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mohler</surname><given-names>E.R.</given-names><suffix>III</suffix></name>
</person-group> (<year>2004</year>) <article-title>Mechanisms of aortic valve calcification</article-title>. <source>Am J Cardiol</source> <volume>94</volume>: <fpage>1396</fpage>–<lpage>1402</lpage>.</citation>
</ref>
<ref id="bibr25-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nordstrom</surname><given-names>P.</given-names></name>
<name><surname>Glader</surname><given-names>C.A.</given-names></name>
<name><surname>Dahlen</surname><given-names>G.</given-names></name>
<name><surname>Birgander</surname><given-names>L.S.</given-names></name>
<name><surname>Lorentzon</surname><given-names>R.</given-names></name>
<name><surname>Waldenstrom</surname><given-names>A.</given-names></name>
<etal/>
</person-group>. (<year>2003</year>) <article-title>Oestrogen receptor α gene polymorphism is related to aortic valve sclerosis in postmenopausal women</article-title>. <source>J Intern Med</source> <volume>254</volume>: <fpage>140</fpage>–<lpage>146</lpage>.</citation>
</ref>
<ref id="bibr26-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Novaro</surname><given-names>G.M.</given-names></name>
<name><surname>Sachar</surname><given-names>R.</given-names></name>
<name><surname>Pearce</surname><given-names>G.L.</given-names></name>
<name><surname>Sprecher</surname><given-names>D.L.</given-names></name>
<name><surname>Griffin</surname><given-names>B.P.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Association between apolipoprotein E alleles and calcific valvular heart disease</article-title>. <source>Circulation</source> <volume>108</volume>: <fpage>1804</fpage>–<lpage>1808</lpage>.</citation>
</ref>
<ref id="bibr27-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ortlepp</surname><given-names>J.R.</given-names></name>
<name><surname>Hoffmann</surname><given-names>R.</given-names></name>
<name><surname>Ohme</surname><given-names>F.</given-names></name>
<name><surname>Lauscher</surname><given-names>J.</given-names></name>
<name><surname>Bleckmann</surname><given-names>F.</given-names></name>
<name><surname>Hanrath</surname><given-names>P.</given-names></name>
</person-group> (<year>2001</year>) <article-title>The vitamin D receptor genotype predisposes to the development of calcific aortic valve stenosis</article-title>. <source>Heart</source> <volume>85</volume>: <fpage>635</fpage>–<lpage>638</lpage>.</citation>
</ref>
<ref id="bibr28-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Osman</surname><given-names>L.</given-names></name>
<name><surname>Yacoub</surname><given-names>M.H.</given-names></name>
<name><surname>Latif</surname><given-names>N.</given-names></name>
<name><surname>Amrani</surname><given-names>M.</given-names></name>
<name><surname>Chester</surname><given-names>A.H.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Role of human valve interstitial cells in valve calcification and their response to atorvastatin</article-title>. <source>Circulation</source> <volume>114</volume>: <fpage>I-547</fpage>–<lpage>I-552</lpage>.</citation>
</ref>
<ref id="bibr29-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Otto</surname><given-names>C.M.</given-names></name>
<name><surname>Kuusisto</surname><given-names>J.</given-names></name>
<name><surname>Reichenbach</surname><given-names>D.D.</given-names></name>
<name><surname>Gown</surname><given-names>A.M.</given-names></name>
<name><surname>O’Brien</surname><given-names>K.D.</given-names></name>
</person-group> (<year>1994</year>) <article-title>Characterization of the early lesion of degenerative valvular aortic stenosis. Histological and immunohistochemical studies</article-title>. <source>Circulation</source> <volume>90</volume>: <fpage>844</fpage>–<lpage>853</lpage>.</citation>
</ref>
<ref id="bibr30-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Parolari</surname><given-names>A.</given-names></name>
<name><surname>Loardi</surname><given-names>C.</given-names></name>
<name><surname>Mussoni</surname><given-names>L.</given-names></name>
<name><surname>Cavallotti</surname><given-names>L.</given-names></name>
<name><surname>Camera</surname><given-names>M.</given-names></name>
<name><surname>Biglioli</surname><given-names>P.</given-names></name>
<etal/>
</person-group>. (<year>2009</year>) <article-title>Nonrheumatic calcific aortic stenosis: an overview from basic science to pharmacological prevention</article-title>. <source>Eur J Cardiothorac Surg</source> <volume>35</volume>: <fpage>493</fpage>–<lpage>504</lpage>.</citation>
</ref>
<ref id="bibr31-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Parolari</surname><given-names>A.</given-names></name>
<name><surname>Tremoli</surname><given-names>E.</given-names></name>
<name><surname>Cavallotti</surname><given-names>L.</given-names></name>
<name><surname>Trezzi</surname><given-names>M.</given-names></name>
<name><surname>Kassem</surname><given-names>S.</given-names></name>
<name><surname>Loardi</surname><given-names>C.</given-names></name>
<etal/>
</person-group>. (<year>2011</year>) <article-title>Do statins improve outcomes and delay the progression of non-rheumatic calcific aortic stenosis?</article-title> <source>Heart</source> <volume>97</volume>: <fpage>523</fpage>–<lpage>529</lpage>.</citation>
</ref>
<ref id="bibr32-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Peacock</surname><given-names>J.</given-names></name>
<name><surname>Levay</surname><given-names>A.</given-names></name>
<name><surname>Gillaspie</surname><given-names>D.</given-names></name>
<name><surname>Tao</surname><given-names>G.</given-names></name>
<name><surname>Lincoln</surname><given-names>J.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Reduced Sox9 function promotes heart valve calcification phenotypes <italic>in vivo</italic></article-title>. <source>Circ Res</source> <volume>106</volume>: <fpage>712</fpage>–<lpage>719</lpage>.</citation>
</ref>
<ref id="bibr33-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Perrotta</surname><given-names>I.</given-names></name>
<name><surname>Russo</surname><given-names>E.</given-names></name>
<name><surname>Camastra</surname><given-names>C.</given-names></name>
<name><surname>Filice</surname><given-names>G.</given-names></name>
<name><surname>Mizio</surname><given-names>G.</given-names></name>
<name><surname>Colosimo</surname><given-names>F.</given-names></name>
<etal/>
</person-group>. (<year>2011</year>) <article-title>New evidence for a critical role of elastin in calcification of native heart valves: immunohistochemical and ultrastructural study with literature review</article-title>. <source>Histopathology</source> <volume>59</volume>: <fpage>504</fpage>–<lpage>513</lpage>.</citation>
</ref>
<ref id="bibr34-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rajamannan</surname><given-names>N.M.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Calcific aortic stenosis: lessons learned from experimental and clinical studies</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <volume>29</volume>: <fpage>162</fpage>–<lpage>168</lpage>.</citation>
</ref>
<ref id="bibr35-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rajamannan</surname><given-names>N.M.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Mechanisms of aortic valve calcification: the LDL-density-radius theory: a translation from cell signaling to physiology</article-title>. <source>Am J Physiol Heart Circ Physiol</source> <volume>298</volume>: <fpage>H5</fpage>-<lpage>H15</lpage>.</citation>
</ref>
<ref id="bibr36-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rajamannan</surname><given-names>N.M.</given-names></name>
</person-group> (<year>2011</year>) <article-title>The role of Lrp5/6 in cardiac valve disease: LDL-density-pressure theory</article-title>. <source>J Cell Biochem</source> <volume>112</volume>: <fpage>2222</fpage>–<lpage>2229</lpage>.</citation>
</ref>
<ref id="bibr37-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rajamannan</surname><given-names>N.M.</given-names></name>
<name><surname>Subramaniam</surname><given-names>M.</given-names></name>
<name><surname>Caira</surname><given-names>F.</given-names></name>
<name><surname>Stock</surname><given-names>S.R.</given-names></name>
<name><surname>Spelsberg</surname><given-names>T.C.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway</article-title>. <source>Circulation</source> <volume>112</volume>: <fpage>I-229</fpage>–<lpage>I-234</lpage>.</citation>
</ref>
<ref id="bibr38-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ramaraj</surname><given-names>R.</given-names></name>
<name><surname>Sorrell</surname><given-names>V.L.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Clinical Review: Degenerative aortic stenosis</article-title>. <source>BMJ</source> <volume>336</volume>: <fpage>550</fpage>–<lpage>555</lpage>.</citation>
</ref>
<ref id="bibr39-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Salas</surname><given-names>M.</given-names></name>
<name><surname>Santana</surname><given-names>O.</given-names></name>
<name><surname>Escolar</surname><given-names>E.</given-names></name>
<name><surname>Lamas</surname><given-names>G.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Medical therapy for calcific aortic stenosis</article-title>. <source>J Cardiovasc Pharmacol Ther</source> [<comment>ePub ahead of print</comment>].</citation>
</ref>
<ref id="bibr40-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schoen</surname><given-names>F.J.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Cardiac valves and valvular pathology: update on function, disease, repair, and replacement</article-title>. <source>Cardiovasc Pathol</source> <volume>14</volume>: <fpage>189</fpage>–<lpage>194</lpage>.</citation>
</ref>
<ref id="bibr41-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Soini</surname><given-names>Y.</given-names></name>
<name><surname>Salo</surname><given-names>T.</given-names></name>
<name><surname>Satta</surname><given-names>J.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Angiogenesis is involved in the pathogenesis of nonrheumatic aortic valve stenosis</article-title>. <source>Hum Pathol</source> <volume>34</volume>: <fpage>756</fpage>–<lpage>763</lpage>.</citation>
</ref>
<ref id="bibr42-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Spargias</surname><given-names>K.</given-names></name>
<name><surname>Milewski</surname><given-names>K.</given-names></name>
<name><surname>Debinski</surname><given-names>M.</given-names></name>
<name><surname>Buszman</surname><given-names>P.</given-names></name>
<name><surname>Cokkinos</surname><given-names>D.</given-names></name>
<name><surname>Pogge</surname><given-names>R.</given-names></name>
<etal/>
</person-group>. (<year>2009</year>) <article-title>Drug delivery at the aortic valve tissues of healthy domestic pigs with a paclitaxel-eluting valvuloplasty balloon</article-title>. <source>J Intervent Cardiol</source> <volume>22</volume>: <fpage>291</fpage>–<lpage>298</lpage>.</citation>
</ref>
<ref id="bibr43-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sun</surname><given-names>Y.A.O.</given-names></name>
<name><surname>Ratajska</surname><given-names>A.</given-names></name>
<name><surname>Weber</surname><given-names>K.T.</given-names></name>
</person-group> (<year>1995</year>) <article-title>Inhibition of angiotensin-converting enzyme and attenuation of myocardial fibrosis by lisinopril in rats receiving angiotensin II</article-title>. <source>J Lab Clin Med</source> <volume>126</volume>: <fpage>95</fpage>–<lpage>101</lpage>.</citation>
</ref>
<ref id="bibr44-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Taylor</surname><given-names>P.M.</given-names></name>
<name><surname>Batten</surname><given-names>P.</given-names></name>
<name><surname>Brand</surname><given-names>N.J.</given-names></name>
<name><surname>Thomas</surname><given-names>P.S.</given-names></name>
<name><surname>Yacoub</surname><given-names>M.H.</given-names></name>
</person-group> (<year>2003</year>) <article-title>The cardiac valve interstitial cell</article-title>. <source>Int J Biochem Cell Biol</source> <volume>35</volume>: <fpage>113</fpage>–<lpage>118</lpage>.</citation>
</ref>
<ref id="bibr45-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Toutouzas</surname><given-names>K.</given-names></name>
<name><surname>Drakopoulou</surname><given-names>M.</given-names></name>
<name><surname>Synetos</surname><given-names>A.</given-names></name>
<name><surname>Tsiamis</surname><given-names>E.</given-names></name>
<name><surname>Agrogiannis</surname><given-names>G.</given-names></name>
<name><surname>Kavantzas</surname><given-names>N.</given-names></name>
<etal/>
</person-group>. (<year>2008</year>) <article-title><italic>In vivo</italic> aortic valve thermal heterogeneity in patients with nonrheumatic aortic valve stenosis. The first <italic>in vivo</italic> experience in humans</article-title>. <source>J Am Coll Cardiol</source> <volume>52</volume>:<fpage>758</fpage>–<lpage>763</lpage>.</citation>
</ref>
<ref id="bibr46-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wallner</surname><given-names>K.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Shah</surname><given-names>P.K.</given-names></name>
<name><surname>Fishbein</surname><given-names>M.C.</given-names></name>
<name><surname>Forrester</surname><given-names>J.S.</given-names></name>
<name><surname>Kaul</surname><given-names>S.</given-names></name>
<etal/>
</person-group>. (<year>1999</year>) <article-title>Tenascin-C is expressed in macrophage-rich human coronary atherosclerotic plaque</article-title>. <source>Circulation</source> <volume>99</volume>: <fpage>1284</fpage>–<lpage>1289</lpage>.</citation>
</ref>
<ref id="bibr47-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Waters</surname><given-names>E.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Allen</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Lanza</surname><given-names>G.</given-names></name>
<name><surname>Wickline</surname><given-names>S.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Detection and quantification of angiogenesis in experimental valve disease with integrin-targeted nanoparticles and 19-fluorine MRI/MRS</article-title>. <source>J Cardiovasc Magn Reson</source> <volume>10</volume>: <fpage>43</fpage>.</citation>
</ref>
<ref id="bibr48-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Xu</surname><given-names>S.</given-names></name>
<name><surname>Liu</surname><given-names>A.C.</given-names></name>
<name><surname>Gotlieb</surname><given-names>A.I.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Common pathogenic features of atherosclerosis and calcific aortic stenosis: role of transforming growth factor-[beta]</article-title>. <source>Cardiovasc Pathol</source> <volume>19</volume>: <fpage>236</fpage>–<lpage>247</lpage>.</citation>
</ref>
<ref id="bibr49-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yang</surname><given-names>X.</given-names></name>
<name><surname>Fullerton</surname><given-names>D.A.</given-names></name>
<name><surname>Su</surname><given-names>X.</given-names></name>
<name><surname>Ao</surname><given-names>L.</given-names></name>
<name><surname>Cleveland</surname><given-names>J.C.</given-names><suffix>Jr</suffix></name>
<name><surname>Meng</surname><given-names>X</given-names></name>
</person-group> (<year>2009</year>) <article-title>Pro-osteogenic phenotype of human aortic valve interstitial cells is associated with higher levels of Toll-like receptors 2 and 4 and enhanced expression of bone morphogenetic protein 2</article-title>. <source>J Am Coll Cardiol</source> <volume>53</volume>: <fpage>491</fpage>–<lpage>500</lpage>.</citation>
</ref>
<ref id="bibr50-1753944712439337">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yetkin</surname><given-names>E.</given-names></name>
<name><surname>Waltenberger</surname><given-names>J.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Molecular and cellular mechanisms of aortic stenosis</article-title>. <source>Int J Cardiol</source> <volume>135</volume>: <fpage>4</fpage>–<lpage>13</lpage>.</citation>
</ref></ref-list>
</back>
</article>